Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2019

At a glance

  • Drugs PB 2452 (Primary) ; Ticagrelor
  • Indications Haemorrhage
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors PhaseBio Pharmaceuticals
  • Most Recent Events

    • 17 Mar 2019 According to a PhaseBio Pharmaceuticals media release, results from this study were presented in a featured clinical research session at the American College of Cardiology's 68th Annual Scientific Session.
    • 17 Mar 2019 According to a PhaseBio Pharmaceuticals media release, results from this study were published in the New England Journal of Medicine.
    • 04 Mar 2019 According to a PhaseBio Pharmaceuticals media release, results from this trial have been selected for presentation during a featured clinical research session at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top